

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

K-252b Ready-Made solution from *Nonomuraea longicatena*

Catalog Number **K2139** Storage Temperature –20 °C

CAS RN: 99570-78-2

Product Description

Molecular Weight: 453.45 Molecular formula: C₂₆H₁₉N₃O₅

K-252b belongs to the K-252 family of compounds, which are general and potent inhibitors of various protein kinases, possibly acting by interfering at or near the ATP binding site. 1 K-252b is an inhibitor of protein kinase A, G, and C. The highest inhibition potency is of protein kinases C with a K_i value of 20 nM, comparable to K-252a (with a K_i value of 18-25 nM). ² Compared to K-252a, K-252b exhibits reduced inhibitory potency for cyclic nucleotide-dependent protein kinases.² K-252b can potentiate the neurotrophin-3-induced tyrosine phosphorylation of Trk on PC12 cells. 1,3 K-252b is also a selective and non-toxic inhibitor of nerve growth factor (NGF) action in the brain. 4 K-252b was found to be as potent as K-252a in inhibiting the nerve growth factorinduced neurite outgrowth on PC12, although it does not permeate the cell membrane as does K-252a. In cultured cortical neurons, K-252b not only blocks the synapse formation but also inhibits the phosphorylation of some cell surface proteins. 6,7 K-252b was used, as a blocker, in studies of the mechanism of ATP-induced long-term potentiation (LTP).8 It was found to markedly reduce the relaxation of the K⁺-contracted rat vas deferens caused by ATP.9

Reagent

K-252b is supplied as a 1 mM solution in DMSO.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store protected from light at -20 °C. Under these conditions the product is stable for 3 years.

References

- Knusel, B., and Hefti, F., J. Neurochem., 59, 1987-1996 (1992).
- 2. Kase, H., et al., *Biochem. Biophys. Res. Commun.*, **142**, 436-440 (1987).
- 3. Knusel, B., et al., *J. Neurochem.*, **59**, 715-722 (1992).
- 4. Knusel, B., and Hefti, F., *J. Neurochem.*, **57**, 955-962 (1991).
- 5. Nagashima, K., et al., *FEBS Lett.*, **293**, 119-123 (1991).
- Kuroda, Y., et al., Neurosci. Lett., 135, 255–258 (1992).
- 7. Muramoto, K., et al., *Biochem. Biophys. Res. Commun.*, **205**, 1467-1473 (1994).
- 8. Fujii, S., et al., Neuroscience, 113, 617-628 (2002).
- Bultmann, R., et al., Eur. J. Pharmacol., 436, 135-143 (2002).

ES,SP,AH,PHC 10/05-1